# Myles Greenberg

> Myles Greenberg is a Series B investor at InCarda Therapeutics backing Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: InCarda Therapeutics
- Location: Salt Lake City, United States
- Total investments: 11
- Last investment: Aug 2014
- Lead investor: 36%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/myles-greenberg/1/bbb/9a
- Website: https://x.com/mylesgreenberg
- Facebook: https://www.facebook.com/myles.greenberg

Myles Greenberg is a Series B investor at InCarda Therapeutics in Salt Lake City focused on Biotechnology and Medical. Myles Greenberg is based out of Salt Lake City, Utah and is the President and CEO of InCarda Therapeutics. Myles previously worked at Alucent Biomedical, Inc. as a President and CEO. Myles Greenberg attended Harvard Business School.

## Contacts

5 contacts available for Myles Greenberg: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/myles-greenberg?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 36% |
| Medical | 3 | 27% |
| Health Care | 3 | 27% |
| SaaS | 1 | 9% |
| Biopharma | 1 | 9% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 27% |
| Series A | 1 | 9% |
| Series C | 1 | 9% |
| Series D | 1 | 9% |
| Funding Round | 1 | 9% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $200M | Private Equity | Aug 04, 2014 |  |
| Vascular Pathways | Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $5M | Debt Financing | Jun 24, 2014 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $55M | Private Equity | Jun 25, 2013 |  |
| Ambra Health | Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England BaptistHospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows. | $5M | Series B | May 16, 2012 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $45M |  | Jan 24, 2012 |  |
| Ambra Health | Ambra Health is a medical data and image management SaaS company. Intuitive, flexible, scalable, and highly interoperable, the Ambra cloud platform is designed to serve as the backbone of imaging innovation and progress for healthcare providers. It empowers health systems such as Memorial Hermann, Stanford Children’s Health, and New England BaptistHospital as well as radiology practices, subspecialty practices, and clinical research organizations to dramatically improve imaging and collaborative care workflows. | $7.5M | Series A | Nov 04, 2010 |  |
| Vascular Pathways | Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $14M | Series B | Nov 01, 2010 |  |
| Vertos Medical | Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $15.5M | Series D | Oct 20, 2009 |  |
| Mevion Medical Systems | Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. | $33M |  | Jan 01, 2009 |  |
| Vertos Medical | Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. | $12M | Series C | Jul 15, 2008 |  |

10 of 11 investments shown.

## Co-investors
- [ProQuest Investments](https://shizune.co/investors/profile/proquest-investments) — VC Fund, 3 deals together
- [Venrock](https://shizune.co/investors/profile/venrock) — VC Fund, 3 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 2 deals together
- [DFJ Mercury](https://shizune.co/investors/profile/dfj-mercury-894f) — VC Fund, 2 deals together
- [MVM Life Science Partners](https://shizune.co/investors/profile/mvm-life-science-partners) — VC Fund, 2 deals together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 1 deal together

## About InCarda Therapeutics

VC Fund · Newark, United States

InCarda Therapeutics is a clinical-stage drug delivery company pioneering a novel approach of treating acute cardiovascular diseases/conditions by the inhalation route. Lead product is InRhythm, an inhaled formulation of an antiarrhythmic drug to treat acute paroxysmal atrial fibrillation events within minutes at home, at work, or anywhere.Completed Phase 1 and currently advancing lead product through Phase 2.InCarda Therapeutics was founded in Newark, California.

5 contacts available at InCarda Therapeutics.

| Name | Title | Profile |
| --- | --- | --- |
| Myles Greenberg | President and CEO | — |
| Anna Popovici | Vice President of Human Resources | — |
| Carlos A. Schuler | Co-Founder, COO and CTO | — |
| Christopher Dufton | SVP of Clinical Development | — |
| Debra S. Echt | Senior Vice President of Medical Affairs | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Myles Greenberg invest in?

Myles Greenberg invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Myles Greenberg?

Public channels for Myles Greenberg include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Myles Greenberg last invest?

The most recent investment recorded for Myles Greenberg closed in Aug 2014. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co